Research use onlyNot for human or veterinary use
Encore Bio Labs CartExplore catalog
ENCORE BIO LABSRESEARCH COLLECTION
Cerebrolysin — complete Encore Bio Labs reference vialMATERIAL / 04

Reference artwork · Legacy packaging may be shown.
Listed identity and formats take precedence over the image.

Research material

Cerebrolysin

A peptide mixture with molecular diversity at its core. Published analysis of a Cerebrolysin sample identified hundreds of peptide sequences. That variety is what makes it scientifically interesting: discovering the components within a complex mixture and the differences between them.

Identity
Peptide mixture

Formats & reference pricing

USD
Listed formatReference price
10 mg vial$69 USD

Reference prices describe the listed formats. They do not confirm availability or constitute an offer for sale.

Review product documentation

For laboratory research only. Not for human or veterinary use.

About the reference identity

A mixture viewed through analytical chemistry

A 2015 analytical study used chromatography and mass spectrometry to identify hundreds of peptide sequences in one Cerebrolysin-labeled sample. Unlike a single, sequence-defined peptide, the name refers to a mixture. That paper characterizes its own sample; it does not establish the composition or origin of this catalog listing.

Reference identity
Peptide mixture, not a single sequence
Analytical context
2015 sample-profiling study

Reference identity only; not a test result for current inventory.

01 / Material overview

The specifications.

Catalog identity
Cerebrolysin
Identity
Peptide mixture
Listed formats
10 mg vial
Reference price range
$69 USD
Intended setting
Qualified laboratory or institutional research
Inventory specifications
Independent inventory review pending

02 / Public regulatory context

Substance identity is not drug approval.

FDA maintains a substance record for Cerebrolysin, but FDA explicitly states that assignment of a UNII does not imply regulatory review or approval.

REGULATORY REFERENCE · STATUS REVIEWED OCT 2026CEREBROLYSIN

An FDA substance record does not establish approval of a drug product.

FDA’s Global Substance Registration System lists Cerebrolysin as a substance and assigns UNII 37KZM6S21G. FDA states on that record that UNII availability does not imply regulatory review or approval. This Encore Bio Labs catalog listing is not represented as an FDA-approved drug product or as equivalent to a clinical or foreign-market product.

Catalog identity
Cerebrolysin
FDA UNII
37KZM6S21G
Catalog format
10 mg vial
FDA approval claim
None
Clinical / foreign-product equivalence
Not represented or established
FDA enforcement context

FDA has cited Cerebrolysin in compounding enforcement where the resulting drug products did not qualify for the referenced 503A exemptions. This page uses that record only to clarify regulatory boundaries and does not provide compounding or human-use guidance.

External public records

FDA GSRS · Cerebrolysin substance record FDA · Compounding enforcement record

03 / Supporting records

Documentation.

Read the Encore summary, the scope of related reports and the status of privacy-redacted supplier copies.

No authenticated certificate establishing current-inventory identity or specifications is published for Cerebrolysin in this catalog.

Encore documentary summary · not a laboratory-issued COA

Report availability
Not located in the reviewed set
Formats & scope
No related report was located in the reviewed set. This does not establish that no document exists elsewhere.
Report authenticity
No report to authenticate
Inventory evidence review
Report-to-inventory correspondence has not been independently established. No purity, quantity or activity result is attributed to current inventory.
Outstanding review
Define the mixture identity and composition and obtain supporting records for the listed formats.
Product-specific SDS
Not located in the reviewed PDF set; applicability and verification pending.

Document inventory reviewed October 6, 2026. Related reports were commissioned by third parties, not Encore. Original customer details and internal records are not included here.

Privacy-redacted supplier report

Report not on file

Where prepared, these are copies redacted by Encore for privacy, not laboratory-issued public versions or Encore-commissioned tests. Analytical content is not replaced with Encore results.

Copy preparation
0 source files in redacted review copies. Duplicate file formats are not additional tests.
Supplier sharing permission
Owner-confirmed for supplied reports; this does not imply a report exists for every product. Report authentication is a separate check.
Privacy review
No source to review. Retained references and copies elsewhere can still identify the original customer; redaction does not guarantee anonymity.
Downloads
No website copy released. No download is available for this product.
Laboratory-issued public copy
Not available. Encore-prepared redactions are not an issuer reissue.

First locate the source report for the material and format; then review privacy, scope and verification.

A public copy does not by itself verify current inventory. No laboratory replacement or delivery date is promised.

Explore summary & report status

04 / A closer look

Common questions.

01Which Cerebrolysin formats and reference prices are listed?

10 mg vial: $69 USD. These are catalog quantities and reference prices, not usage instructions, stock confirmation or an offer for sale.

02Where can I find the Cerebrolysin reports?

Report not on file. The Documentation section on this page lists the reviewed source status and outstanding items for this material. No public PDF is available for this product; an unreleased or missing document is not a certificate of current inventory.

03Does an FDA substance identifier mean Cerebrolysin is FDA-approved?

No. FDA's substance-registration system explicitly states that assignment of a UNII does not imply regulatory review or approval.

04Does this catalog represent Cerebrolysin as an approved U.S. drug product?

No. This catalog does not represent Cerebrolysin as an FDA-approved drug product, and it makes no equivalence claim to any clinical or foreign-market product.

05What has FDA said about Cerebrolysin in compounding enforcement?

FDA has cited Cerebrolysin in compounding enforcement as a bulk substance that did not qualify for the referenced 503A exemptions in that action. This page does not provide compounding, dosing, injection, cognitive, neurologic, or therapeutic guidance.

06Does the image or name establish the composition of a current lot?

No. Exact mixture identity, composition and component quantities require supporting records; no related report was located in the reviewed set.

Continue the collection

Next in the catalog.

View all materials